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Membrane association and release of wild-type and
pathological tau from organotypic brain slice cultures
Cara L Croft1, Matthew A Wade1, Ksenia Kurbatskaya1, Pavlina Mastrandreas1, Martina M Hughes1, Emma C Phillips1, Amy M Pooler1,3,
Michael S Perkinton2, Diane P Hanger1 and Wendy Noble*,1
The spatiotemporal transmission of pathological tau in the brain is characteristic of Alzheimer’s disease. Release of both soluble
and abnormal tau species from healthy neurons is increased upon stimulation of neuronal activity. It is not yet understood whether
the mechanisms controlling soluble tau release from healthy neurons is the same as those involved in the spread of pathological
tau species. To begin to understand these events, we have studied tau distribution and release using organotypic brain slice
cultures. The slices were cultured from postnatal wild-type and 3xTg-AD mice for up to 1 month. Tau distribution in subcellular
compartments was examined by western blotting, and tau release into culture medium was determined using a sensitive sandwich
ELISA. We show here that 3xTg-AD cultures have an accelerated development of pathological tau abnormalities including the
redistribution of tau to synaptic and membrane compartments. The 3xTg-AD slice cultures show elevated basal tau release relative
to total tau when compared with wild-type cultures. However, tau release from 3xTg-AD slices cannot be further stimulated when
neuronal activity is increased with potassium chloride. Moreover, we report that there is an increased pool of dephosphorylated
membrane-associated tau in conditions where tau release is increased. These data suggest that there may be differential patterns
of tau release when using integrated slice culture models of wild-type and transgenic mouse brain, although it will be important to
determine the effect of tau overexpression for these findings. These results further increase our knowledge of the molecular
mechanisms underlying tau release and propagation in neurodegenerative tauopathies.
Cell Death and Disease (2017) 8, e2671; doi:10.1038/cddis.2017.97; published online 16 March 2017
The characteristic progressive accumulation of tau pathology
in affected brain regions during the development of Alzhei-
mer’s disease (AD) is believed to result from the spread of
aggregated tau along anatomically connected pathways.1–3
Restricted expression of transgenic tau in the entorhinal
cortex results in both local accumulation of aggregated tau
resulting in neuron loss, and the trans-synaptic spread of tau
aggregates tomore distal regions of the brain.4,5 The spread of
pathological tau and the extent of neurotoxicity in this model is
also further accelerated by the presence of Aβ.6 The precise
mechanisms of tau spread are not yet fully understood,
however, the species of tau involved appears to be critical,2 as
are the extracellular vesicles such as exosomes in which tau
can be compartmentalised in different phosphorylation
states.7–9 Synaptic connectivity, rather than the proximity of
neurons, appears to be critical for tau propagation,10 and
therefore understanding the routes by which tau is released
from neurons is important for elucidating how pathological tau
spreads through the brain in AD and other tauopathies.
We previously showed that tau release from neurons is a
physiological process that is stimulated by neuronal activity in
cultured rat neurons.11 Similar findings have since been
reported in vivo.12 The relationship between tau release and
neuronal activity appears to be bi-directional since both
extracellular tau and Aβ feedback to neurons to perpetuate
further tau release.13 Released endogenous tau is reported to
be released free in a dephosphorylated full-length form11
or as N-terminally truncated fragments.13,14 A small proportion
of tau released under these conditions is associated with
ectosomes, plasma membrane-derived vesicles.15 Particu-
larly when tau is exogenously expressed or in a highly
phosphorylated misfolded state, it is released from cells in
association with exosomes7,16 and can be highly
phosphorylated.17 The apparent discrepancies in these
findings raise the question of whether physiological species
of soluble tau are released via the same mechanisms as are
involved in the propagation of pathological tau forms.
To investigate these mechanisms further, we have exam-
ined tau release from organotypic brain slice cultures prepared
from wild-type and 3xTg-AD mice.18,19 Recent publications
have highlighted the utility of using organotypic nervous tissue
slices for modelling neurodegenerative diseases. Organotypic
brain slice cultures from transgenic models of AD develop
some of the main molecular hallmarks of human disease
including 'plaque-like' depositions when prepared from APP
transgenic mice,20 and abnormally phosphorylated tau when
tau overexpressing mice are used.21,22 Moreover, these
models can be used to examine the cellular mechanisms
underlying AD including Aβ-mediated synaptotoxicity.23–26
We show here for the first time that organotypic brain slices
cultured from postnatal 3xTg-AD pups show accelerated
development of AD-like molecular pathology. Notably,
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3xTg-AD slices exhibit increased basal tau release relative to
total tau amounts when compared with wild-type slices.
Stimulation of neuronal activity with KCl increased tau release
from wild-type slices, in line with reports in primary neurons
and in vivo,11,12 whereas the extent of tau release from 3xTg-
AD slices was unchanged by KCl stimulation. In both wild-type
and 3xTg-AD slices, there was a marked correlation between
the amount of dephosphorylated tau present at membranes
and the extent of tau release, in keeping with reports that tau
localisation is important for its propagation.27 Taken together,
these results suggest that the mechanisms governing the
release of physiological and pathological forms of tau may be
differentially regulated by neuronal stimulation. These findings
might support the existence of functionally distinct pools of
extracellular tau with physiological tau contributing to neuronal
signalling in a healthy brain environment28 and pathological
tau driving the spread of tau pathology in diseased brain.
However, potential effects of overexpression on tau localisa-
tion and release must be taken into account when interpreting
the results of this work as it is possible that saturation of
synaptic activity is responsible for the lack of effect of neuronal
stimulation on tau release from 3xTg-AD slices.
Results
Organotypic brain slice cultures from 3xTg-AD mice
recapitulate molecular phenotypes of aged brain. We first
determined the extent to which organotypic brain slice
cultures prepared from 3xTg-AD mice recapitulate the
neurodegenerative molecular changes that develop
in vivo18,19 and in human AD brain.29 Cortical extracts from
3xTg-AD mice showed overexpression of total tau, as
expected on the basis of human tau overexpression
(Figure 1a). At the ages examined here, no significant
increases in tau phosphorylation at CP13 (Ser202) or PHF1
(Ser396/404) were observed, in line with previous reports.30
However, an increased abundance of sarkosyl-insoluble tau
was apparent in 12-month-old 3xTg-AD cortex (Figure 1b), as
described previously.18,19,31,32 The 3xTg-AD cortex also sho-
wed a progressive accumulation of total APP and Aβ1-42
relative to age-matched wild-type controls (Figure 2a), similar
to that previously described by Oddo et al.19
Cultured brain slices from 3xTg-AD mice were charac-
terised by an accumulation of total tau (Figure 1c), similar to
that observed in aged brain.19 14–28 days in vitro (DIV) slices
also displayed significant increases in tau phosphorylation at
Ser202 and Ser396/404 relative to wild-type controls, with
these epitopes being hyperphosphorylated in AD brain.33
These data suggest accelerated disease-associated tau
phosphorylation in cultured brain slices in comparison to
in vivo aged 3xTg-AD brain, as previously reported for other
tau transgenic lines.22 In support of this, an accumulation of
approximately 64 kDa tau (Figure 1c) was apparent in 3xTg-
AD slices at 21 DIV (Figure 1d). Such higher molecular weight
tau species precede the accumulation of sarkosyl-insoluble
material in several tau transgenic lines.34,35 Tau in 3xTg-AD
slices was not limited to axons but showed a somatodendritic
appearance, characteristic of tau localisation in AD
(Figure 1e). 3xTg-AD brain slice cultures also showed
increased expression of APP at 14 DIV and over-production
of Aβ1-42 when aged for 28 DIV (Figure 2b). It is possible that
the increased APPobserved in slice cultures at relatively early
DIV represents a synaptic compensation response, similar to
that recently reported during AD progression.29 We have
previously shown that sustained culture over months allows
the development of small diffuse plaques in other APP
transgenic lines.22
Synaptosomes were prepared from mouse brain and slice
cultures to allow examination of protein association with
synaptic compartments. We have previously demonstrated
the enrichment of synaptic proteins in the synaptosomal
fraction relative to the non-synaptosomal fraction using this
protocol.36 No changes in post-synaptic markers, even in the
oldest 3xTg-AD animals examined here (12 months of age,
Figure 3a), were detected in synaptosomes isolated from
3xTg-AD and wild-type cortex. This is in keeping with previous
analysis reporting no alterations in synapse density or
synapse contact area in 13-month-old 3xTg-AD mice.37
Interestingly, when synaptosome preparations were immuno-
blotted with antibodies against tau and APP, the results
suggested a transient trend towards upregulation of tau in the
synaptic compartment in young (1–2-month-old) mice that
was lost with aging (Figure 3b). APP was also somewhat
increased in synapses; the increases at 1, 2 and 9 months
being significantly different when compared with wild-type
(Figure 3b).
In 3xTg-AD slices, no reductions in PSD-95 and synapto-
physin amounts were apparent in immunoblotted synapto-
somes, suggesting that synapses remaining in these cultures
are relatively healthy and intact (Figure 3c). However, these
slice cultures also showed a transient redistribution of tau into
synaptic compartments in 14 DIV slices relative to controls
(Figure 3d). This likely represents a redistribution rather than
passive process as tau levels in the synapses are not
sustained, unlike the levels of tau overexpression observed
in 3xTg-AD slices that are only significantly increased from
wild type from 21 DIV (Figure 1c). Such redistribution of tau to
synapses was recently shown to be an important biological
correlate of dementia in AD,38 and suggests that some
AD-relevant changes may be recapitulated in this slice culture
model. There were no changes in APP abundance at
synapses over 28 days in culture (Figure 3d). Again, the
abundance of APP at synapses does not appear to be
associated with APPoverexpression in these slices since total
APP was significantly elevated relative to wild type at 14 DIV,
at which time there was no increase in synaptic APP.
3xTg-AD slice cultures show increased levels of basal
tau release. We next assessed basal tau release from 3xTg-
AD slice cultures in comparison with that from wild-type
controls. Total amounts of tau released into medium over a
period of 30 min were measured using an in-house total tau
ELISA that uses two commercially available tau antibodies
with epitopes in the middle region (BT2) and C-terminal half
(Dako) of tau. Intracellular tau amounts were determined in
the same cultures by immunoblotting, as described above.
The amounts of tau detected in culture medium were then
normalised to amounts of intracellular tau in the same sample
to control for the effects of tau overexpression in the 3xTg-AD
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slices and to allow the proportion of total tau released from
slices to be determined. In addition, the amount of lactate
dehydrogenase (LDH) released into the media from the same
slices was measured to ensure that changes in tau release
are not a result of increased cell death. The LDH content in
culture medium was calculated as a proportion of the total
LDH in the slice culture lysates plus that measured in medium.
The 3xTg-AD slice cultures were found to release a
significantly larger proportion of tau under basal conditions
compared with wild-types (Figure 4a). There were no
significant differences in LDH release (Figure 4b). These data
suggest that disease-associated forms of tau are released
from healthy neurons more readily than ‘normal’ tau under
basal conditions.
Figure 1 Organotypic brain slice cultures from 3xTg-AD mice show accelerated development of tau abnormalities. Representative western blots of cortical brain lysates
prepared from 1-, 2-, 4-, 9- and 12-month-old wild-type and 3xTg-AD mice, probed with antibodies against tau (both non-phosphorylated and phosphorylated), PHF1 (phospho-
Ser396/404), Tau-1 (dephospho-Ser199/202/Thr205) and CP13 (phospho-Ser202). Blots were also probed with an antibody against β-actin as a loading control. Bar charts show
amounts of total tau relative to β-actin, and phospho-tau as a proportion of total tau, n= 3. (b) Sarkosyl-insoluble tau was isolated from 4- and 12-month-old wild-type (WT) and
3xTg-AD mice. Western blots show tau in the low-speed supernatant and sarkosyl-insoluble fraction. The amount of sarkosyl-insoluble relative to total tau in low-speed
supernatants is shown in the bar chart, n= 3. (c) Lysates were prepared from wild-type and 3xTg-AD brain slice cultures at 14, 21 and 28 days in vitro (DIV), n= 12. Blots were
probed with total tau and phosphorylation-dependent tau antibodies. An antibody against β-actin was used as a loading control. Bar charts show amounts of total tau relative to
β-actin, and phospho-tau as a proportion of total tau (Dako), n= 12. (d) Bar chart shows the amount of 64 kDa tau in wild-type and 3xTg-AD brain slice cultures as detected by the
total tau antibody (indicated by arrowhead), quantified as a proportion of total tau, n= 12. (e) Immunohistochemistry showing neurons in 28 DIV 3xTg-AD slices labelled with
antibodies against total tau and tau phosphorylated at Ser202 (CP13). Scale bar is 20 μm. Data for all graphs are mean± S.E.M. and is shown as fold change from wild-type
(fold WT). *Po0.05, **Po0.01, ***Po0.001
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Neuronal stimulation increases tau release from
wild-type, but not 3xTg-AD brain slice cultures. To assess
the effects of neuronal stimulation on the release of normal
and disease-associated tau from organotypic brain slice
cultures, 50 mM KCl was applied to depolarise neurons and
stimulate neuronal activity over a period of 30 min. No signifi-
cant differences in LDH release between depolarised and
non-depolarised wild-type and 3xTg-AD slice cultures was
found, suggesting any increased tau release was not a result
of increased cell death (Figure 4d). When stimulated with
KCl, wild-type slice cultures showed significant increases in
tau release compared with non-stimulated wild-type slice
cultures (Figures 4c, Po0.05), in agreement with published
data from dissociated rodent cells11 and in vivo in wild-type
mice.12 In contrast, 3xTg-AD slice cultures stimulated with
KCl did not demonstrate any further release of tau when
compared with non-stimulated 3xTg-AD slice cultures
(Figure 4d).
Bright et al.13 reported that secreted human tau positively
feeds back to neurons to cause further neuronal activity and
stimulate Aβ production over the course of 20 days. We
therefore measured Aβ amounts in slice cultures stimulated
with KCl for 30 min, but we found no changes in the amount of
Aβ1-40 or Aβ1-42 in KCl-treated cultures in comparison with
controls (Figure 4e). It is possible that longer periods of
stimulation may have affected Aβ release from slices, but this
was not determined here.
The presence of dephosphorylated tau at neuronal
membranes is associated with the extent of tau release
from brain slice cultures. Although generally considered to
be cytosolic, a significant proportion of tau is associated with
plasma membranes.39,40 Membrane-associated tau is
predominantly dephosphorylated at serine and threonine
residues.40,41 As some of the vesicles (ectosomes,
exosomes) associated with tau release originate at the
plasma membrane, it was of interest to investigate the
proportions of tau at membranes in wild-type and 3xTg-AD
slices to determine whether there is any association with tau
release. Differential centrifugation was used to prepare
membrane and cytosol fractions that were then immuno-
blotted with antibodies against tau. In 3xTg-AD slice cultures,
both the membrane and cytosolic fractions contained
significantly more tau than controls due to tau overexpression
in this line. However, when the ratio of membrane:cytosolic
tau was calculated, 3xTg-AD slices had a significantly smaller
proportion of tau associated with membranes when com-
pared with that in wild-type slice cultures (Figure 5a).
However, the proportion of tau dephosphorylated at the
Tau-1 epitope was increased in the membrane fraction of
3xTg-AD slices compared with controls (Figure 5a), an
environment in which these slices also show elevated tau
release relative to that of wild-type slice cultures.
Membrane and cytosolic fractions were next prepared from
wild-type and 3xTg-AD slice cultures at 28 DIV treated with
vehicle or 50 mM KCl to induce depolarisation. In both wild-
Figure 2 Organotypic brain slice cultures from 3xTg-AD mice show altered APP and Aβ. (a) Representative western blots of cortical brain lysates prepared from 1-, 2-, 4-,
9- and 12-month-old wild-type and 3xTg-AD mice, probed with an antibody against N-terminal APP (22c11). Blots were also probed with an antibody against β-actin as a loading
control. Bar chart shows amounts of APP relative to β-actin as fold change from wild-type (fold WT). Aβ ELISAs were used to measure Aβ1-40 and Aβ1-42 content. Bar charts
show Aβ amounts as pg/ml, n= 3. (b) Lysates were prepared from wild-type and 3xTg-AD brain slice cultures at 14, 21 and 28 days in vitro (DIV), n= 12. Blots were probed with
the 22c11 antibody against APP. An antibody against β-actin was used as a loading control. Bar chart shows amounts of APP relative to β-actin in each sample as fold change
from control (fold WT), n= 9. Aβ1-40 and Aβ1-42 amounts as pg/ml in brain slice cultures are also shown, n= 12. Data are mean±S.E.M. *Po0.05, **Po0.01
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type and 3xTg-AD slice cultures treated with KCl, the ratio of
total tau present in the membrane fraction relative to the
cytosolic fraction did not differ from control treatment
(Figure 5b). However, in wild-type slice cultures treated with
KCl, the amount of membrane-associated tau dephosphory-
lated at the Tau-1 epitope was significantly increased
compared with control treatment (Figure 5b), indicating an
increased association of dephosphorylated tau with mem-
branes following neuronal stimulation, conditions under which
tau release was increased.
In contrast, in 3xTg-AD slice cultures treated with KCl, no
changes in membrane-associated tau dephosphorylated at
Tau-1 were observed (Figure 5b), conditions under which tau
release is also not increased above basal levels. Taken
together, these data suggest that conditions leading to an
increased pool of dephosphorylated tau at membranes are
associated with elevated tau release from slice cultures. In
addition, these data further suggest that differences in the
effect of neuronal stimulation on tau release from tissues
containing normal or disease-associated tau might be related
to the subcellular localisation of pools of dephosphorylated
tau.
The cleavage of tau is a post-translational modification,
which can affect tau function, with some fragments acting as
seeds which promote tau aggregation,42 altered tau clear-
ance, and, in vivo, changes in cognition and motor ability.43
Tau cleaved at both its N- and C-termini has been detected in
AD brain.44 Currently, no consensus exists on whether intact,
N-terminally or C-terminally truncated tau is the species of tau
that propagates. Endogenous tau released under basal
conditions from primary cortical rat neurons is predominantly
full length,11 although some truncated species have been
identified together with full-length tau.15 However, others show
that only C-terminally truncated forms of endogenous tau are
Figure 3 Organotypic brain slice cultures from 3xTg-AD mice accumulate tau in synaptic compartments. Representative western blots of proteins in the synaptosome
fractions prepared from 1-, 2-, 4-, 9- and 12-month-old wild-type and 3xTg-AD brain. Blots were probed with antibodies against (a) synaptophysin and PSD-95 and (b) APP
(22c11) and total tau, n= 3. Bar charts show amounts of protein in the synaptic fraction following normalisation to β-actin in each sample. Western blots of proteins in the
synaptosome fractions prepared from wild-type (WT) and 3xTg-AD brain slice cultures at 14, 21 and 28 DIV. Blots were probed with antibodies against (c) synaptophysin and
PSD-95 and (d) APP (22c11) and total tau, n= 9. An antibody against β-actin was used as a loading control. Bar charts show amounts of protein in the synaptic fraction. Data are
shown as fold change from wild-type at each time point. Data are mean±S.E.M. **Po0.01, ***Po0.001
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secreted from unstimulated human and rodent neurons.14 In
contrast, pathological extracellular tau in a rat model of
tauopathy contains tau lacking the C terminus but containing
the N terminus,15 and C-terminally truncated tau is released
fromAD synaptosomes.45 In addition, exogenously expressed
hyperphosphorylated tau secreted from non-neuronal cells
was demonstrated to be C-terminally cleaved.17
To determine which species of tau are associated with
membranes, the membrane fractions prepared from 28 DIV
wild-type and 3xTg-AD slice cultureswere immunoblotted with
primary antibodies directed against the N terminus (TP007)
and C terminus (TP70) of tau.46,47 Membranes of both wild-
type and 3xTg-AD slice cultures contain predominantly full-
length tau species of 50–64 kDa with intact N- and C- termini
(Figure 5c). However, some smaller tau species of approxi-
mately 35–40 kDa and 28–30 kDa were detected by the
TP007 and TP70 antibodies, respectively, indicating that some
C-terminally and N-terminally truncated tau species are also
present at membranes in both wild-type and 3xTg-AD slices.
There were no marked differences in the tau species detected
between genotypes, indicating that phosphorylation or con-
formation of tau is likely more important for determining the
dynamics of tau release from these slice cultures. Finally, to
confirm the stringency of the fractionation, cytosolic and
membrane preparations were probed for membrane-
associated flotillin and cytosolic α-tubulin (Figure 5d). As
expected, flotillin-1 was primarily localised in the membrane
fraction, whereas α-tubulin was enriched in the cytosol.
Discussion
The results presented show for the first time that slice cultures
from 3xTg-AD mice show progressive and accelerated
development of AD-like alterations in APP, tau and synaptic
proteins that mirror pathology development in 3xTg-AD mice
in vivo and human AD. In particular, we show the presence of
highly phosphorylated and higher molecular weight tau
species in 3xTg-AD slices relative to age-matched wild-type
controls. Indeed, higher phosphorylation of tau was found in
Figure 4 Organotypic brain slice cultures from 3xTg-AD and wild-type mice show differential tau release responses to neuronal stimulation. Tau and LDH release into the
culture medium of 28 DIV wild-type (WT) and 3xTg-AD slice cultures were measured. (a) Bar chart shows amounts of tau released into the media under basal (non-stimulated)
conditions, after standardisation to total intracellular tau amounts in the same sample. (b) Release of lactate dehydrogenase (LDH) into media under basal conditions was
measured as an indicator of slice viability. (c) Tau release into culture medium following stimulation with control or 50 mM KCl for 30 mins and (d) LDH release under these
conditions. (e) Bar charts show Aβ1-40 and Aβ1-42 amounts in culture medium following treatment with 50 mM KCl or control. Data are shown as fold change from WT slice
cultures in (a and b). Data are fold change from control treatment in (c and d). Mean± S.E.M. is shown, n= 12–24, *Po0.05
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slices compared with in vivo. This appears to be a common
phenomenon in primary and slice culture models that is likely
to result from the stress of culture preparation and/or the
presence of medium components that can affect tau
phosphorylation signalling pathways, including insulin, gluta-
mate and horse serum.22
Using this culture system as a means to probe the effect of
pathological tau alterations on its pattern of release, we show
Figure 5 Association of dephosphorylated tau at membranes with tau release. (a) Representative western blots of membrane and cytosol fractions prepared from WTand
3xTg-AD slice cultures under basal conditions showing total (phosphorylated and non-phosphorylated) tau and tau dephosphorylated at Ser199/202/Thr205 (Tau-1). Bar charts
show relative total tau amounts in the membrane and cytosolic fraction and the ratio of membrane/cytosolic tau. The amount of Tau-1 as a proportion of total tau is also shown for
these fractions. Data are shown as fold change from wild-type (WT) slice cultures, n= 12. (b) Representative western blots of membrane and cytosol fractions prepared from WT
and 3xTg-AD slice cultures after stimulation with 50 mM KCl or vehicle for 30 min. Blots showing amounts of total tau and tau dephosphorylated at the Tau-1 epitope relative to
total tau (Dako) in membrane and cytosolic fractions are shown, as well as graphs showing the ratio of membrane/cytosol tau. Data are shown as fold change from wild-type (WT).
Data are mean±S.E.M., n= 12, *Po0.05, **Po0.01. (c) Representative western blots of membrane fractions prepared from 28 DIV wild-type and 3xTg-AD slice cultures
showing N-terminally intact (TP007) and C-terminally intact (TP70) tau at 50–64 kDa. Some smaller fragments of tau were apparent at approximately 37 and 30 kDa. (d) Western
blots showing enrichment of the membrane protein flotillin and the cytosolic protein α-tubulin in the membrane and cytosolic fractions, respectively
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that 3xTg-AD slices release almost two-fold the amount of tau
released by wild-type slice cultures in basal conditions, after
normalising against total amounts expressed in 3xTg-AD
slices. It should be noted that it was not possible to account for
possible differences in tau localisation or association with
membrane-associated vesicles in these experiments. Over-
expression of tau has previously been shown to result in
release of highly phosphorylated tau17 from cells, often in
association with exosomes7,16 and it will be of great interest to
next determine whether tau released from 3xTg-AD slices is
aberrantly phosphorylated and/or cleaved relative to tau
released from wild-type slices. Regardless of the species
involved, it is likely that the extracellular tau, released by an as-
yet undefined mechanism, contributes to tau propagation in
disease as demonstrated previously in several AD and
tauopathy models.5,48–50
The results also demonstrate that 3xTg-AD slice cultures
contain a greater proportion of dephosphorylated tau at
membranes as shown by increased abundance of tau
dephosphorylated at the Tau-1 site in this fraction. Although
it has not been possible to explore the exact relationship
between membrane-associated tau and tau release in this
work, previous studies have suggested that tau is held at the
membrane before it is released, potentially in association with
exosomes7,8,16 or ectosomes.15 In agreement with our work,
tau species at the membrane have previously been identified
as being predominantly dephosphorylated at serine and
threonine residues when compared with cytosolic tau,40 and
increased phosphorylation of tau, particularly at N-terminal
residues, reduces its association with the membrane.41 Taken
together, this suggests that these largely dephosphorylated
species of tau may be awaiting secretion, as it has been
demonstrated that both physiological and pathological extra-
cellular tau species are predominantly dephosphorylated
compared with species found intracellularly.11,17 It remains to
be determined which species of tau are released by wild-type
and 3xTg-AD slice cultures, and the precise mechanisms by
which they are released.
Stimulating neuronal activity with KCl was shown here to
significantly increase tau release from wild-type slice cultures,
but not to stimulate any further increases in tau release from
3xTg-AD slice cultures. Increased release of tau after
neuronal depolarisation has previously been shown in both
wild-type rat primary cortical neurons11 and in vivo in wild-type
mice.12 The reasons why KCl does not stimulate further tau
release from 3xTg-AD slices are not yet identified, but may be
a result of saturation of synaptic activity in 3xTg-AD slices as
Aβ is known to cause increased cellular hyperexcitability.47,48
Similarly, Aβ has been shown to accelerate the propagation of
tau in vivo.49 Therefore, it is conceivable that increased
synaptic activity in the 3xTg-AD slices, reflective of conditions
in AD brain, underlies the differences in tau release observed
here following neuronal stimulation. However, increased tau
release was found to occur upon KCl depolarisation of
synaptosomes isolated from human AD, but not control,
brain,45 in apparent disagreement with the data presented
here. In this context, it is worth remembering that 3xTg-AD
mice express P301L FTLD-tau and tau-associated neurode-
generation appears to differ in AD and FTLD-tau. Synapse
and cell loss is more abundant in FTLD despite the number of
NFTs beingmarkedly less than those found in affected regions
of AD. Thus, it is important to replicate these findings using a
mousemodel that overexpresseswild-type human tau such as
the htau51 or Tau3543 lines.
It should also be noted that Sokolow et al.45 measured tau
release only from synapses, as compared with the integrated
and functionally connected neural cells present in slice
cultures. It is possible that the increased phosphorylation of
tau in 3xTg-AD slices changes its subcellular distribution such
that an increased pool of tau is docked at membranes in
readiness for release, and this cannot be further increased by
neuronal stimulation. In partial support of this idea, increased
tau release upon KCl treatment of wild-type slices was
associated with increased amounts of membrane-associated
dephosphorylated tau. This might therefore argue that both
physiological and pathological tau release occur, at least in
part, via a common mechanism that involves accumulation of
dephosphorylated tau at membranes. There were no changes
in the amounts of dephosphorylated tau at membranes on KCl
stimulation of 3xTg-AD slices, conditions under which no
elevated tau release was observed.
The data presented here demonstrate that organotypic
brain slice cultures from 3xTg-AD mice rapidly develop
AD-relevant disease features and can be used as a model
in vitro system to study some aspects of both tau and Aβ
pathology. In addition, we demonstrate that slice cultures are
an ideal model with which to investigate the processes
associated with the propagation of tau in AD.
Materials and Methods
All materials were obtained from Sigma (Poole, Dorset, UK) unless otherwise stated.
Organotypic brain slice culture. Organotypic brain slice cultures were
prepared from postnatal day 8–9 3xTg-AD18,19 and background control wild-type
mice as previously described.22 Culture medium was changed every 2–3 days. The
slices were treated after 28 days in culture.
Cell death assays. Cytotoxicity was evaluated by measuring lactate
dehydrogenase (LDH) in culture medium using Cytotox 96 assay kits (Promega,
Madison, WI, USA) according to the manufacturer’s directions. LDH content in
medium and lysed slice cultures was measured to determine the total LDH content.
Optical density was measured at 492 nm (Wallac 1420 Victor3 plate reader,
PerkinElmer, Waltham, MA, USA). LDH release from slice cultures was calculated
as a percentage of total LDH in each well.
Preparation of slice culture lysates for western blotting. After
treatments, the medium was removed and the slices were washed in ice-cold
phosphate-buffered saline (PBS) followed by lysis in extra strong lysis buffer (10 mM
Tris-HCl (pH 7.5), 0.5% (w/v) sodium dodecyl sulphate (SDS), 20 mM sodium
deoxycholate, 1% (v/v) Triton X-100, 75 mM sodium chloride, 10 mM ethylenedia-
minetetraacetic acid (EDTA), 2 mM sodium orthovanadate, 1.25 mM sodium fluoride
and protease inhibitor cocktail for mammalian tissues (Roche Diagnostics, Burgess
Hill, UK)), and centrifugation at 16 000 × gav for 20 min at 4 °C. The protein
concentration of supernatants was measured using a BCA protein assay kit (Pierce
Endogen, Rockford, USA) and the samples were standardised to equal protein
concentration before being analysed by SDS-PAGE.
Subcellular fractionation. Cytosol and membrane fractions were prepared
as previously described.40 In brief, the cells were scraped into hypotonic buffer
(10 mM sodium bicarbonate containing 20 mg/ml deoxyribonuclease I, 1 mM sodium
orthovanadate and Complete protease inhibitor cocktail (Roche, Mannheim,
Germany)) and disrupted by sonication (five strokes with probe sonicator) on ice.
The lysates were centrifuged at 720 × g(av) for 5 min at 4 °C, to remove unbroken
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cells, and the resultant supernatants were centrifuged at 100 000 × g(av) for 1 h at
4 °C. The final supernatant (‘cytosolic fraction’) was mixed with Laemmli sample
buffer and the pellet (‘membrane fraction’) was resuspended in the same buffer.
The samples were normalised for total protein content following measurement of
protein amounts using a BCA protein assay kit (Pierce Endogen, Rockford, IL, USA)
before use.
Preparation of synaptosomes. Synaptosomes were prepared as
previously described.52 In brief, the slices were homogenised in synaptosome
lysis buffer (10 mM Tris-HCl pH 7.4, containing 0.32 M sucrose, 2 mM EGTA, 2 mM
EDTA and Complete protease inhibitor cocktail (Roche, Mannheim, Germany)) and
centrifuged at 1000 × g(av) for 10 min at 4 °C to remove cell nuclei and debris. The
supernatant (‘total fraction’) was then centrifuged at 10 000 × gav for 20 min at 4 °C.
The final supernatant (‘non-synaptosomal’) was mixed with Laemmli sample buffer
and the pellet (‘synaptosomal fraction’) was resuspended in the same buffer.
Tau ELISA. The slice culture medium was replaced with Hank’s Balanced Salt
Solution (Life Technologies Ltd, Paisley, UK). The slices were treated with the indicated
compounds diluted in HBSS. HBSS was collected from neurons and centrifuged at
12 000 g for 10 min at 4 °C to remove cell debris. Tau content in HBSS was
determined by ELISA using a combination of a polyclonal total tau primary antibody
(Dako, Ely, UK; cat #A0024 RRID:AB_10013724) and mouse monoclonal total tau
antibody (BT2, Fisher Scientific, Loughborough, UK; cat #MN1010 RRID:
AB_10975238) according to methods adapted from ref. 14. In brief, 96-well Nunc
Maxi-Sorp plates were coated with 2 μg/ml BT2 for 8 days at 4 °C with shaking.
Starting blocking buffer (Thermo Scientific Ltd, Loughborough, UK) was added for 4 h
at ambient temperature with shaking, followed by application of conditioned HBSS from
slice cultures overnight at 37 °C. Following washing, the capture antibody (Dako) was
added and incubated overnight at ambient temperature with shaking. Secondary
antibody (horseradish peroxidase (HRP)-labelled anti-rabbit IgG (GE Healthcare, Little
Chalfont, UK)) was added for 1 h at ambient temperature with shaking and a stabilised
chromogen TMB substrate solution (Thermo Scientific Ltd, Loughborough, UK) was
added for detection. Absorbance was read at 450 nm with a Wallac 1420 Victor3
multilabel plate reader (PerkinElmer).
Aβ ELISA. Quantification of Aβ1-40 and Aβ1-42 in slice lysates was performed
using ELISA kits from Invitrogen (Paisley, UK) (Aβ1-40 ELISA KHB3481; Aβ1-42
ELISA KHB3442) as we have previously described.53
SDS-PAGE and immunoblotting. A total 5–20 μg protein was separated
on 10% or 12% (w/v) SDS-PAGE gels and electrophoretically transferred to
nitrocellulose membrane, as we have described previously.29 White lines separating
lanes in some immunoblots indicate removal of portions of the blots for clarity and/or
splicing together of distinct blots. The following primary antibodies were used for
western blotting. Total tau (rabbit IgG; Dako Ltd.; cat #A0024 RRID:AB_10013724);
APP (mouse IgG1, clone 22c11; Millipore UK Ltd; Watford, UK; cat #AB5352 RRID:
AB_91793); APP (mouse IgG1, clone 6E10; Covance Research Products; cat
#SIG-39300-200 RRID:AB_10175290); synaptophysin (mouse IgM, clone SP15;
Enzo Life Sciences, Exeter, UK; cat #ADI-VAM-SV011-F RRID:AB_11177905);
PSD-95 (rabbit IgG, Cell signaling, Danvers, MA, USA; cat #2507 RRID:
AB_561221); β-actin (mouse IgG1, clone AC-15, Abcam, Cambridge, UK; cat
#ab40864 RRID:AB_722536). The following tau antibodies were kindly gifted by
Peter Davies (Albert Einstein College of Medicine, Bronx, NY, USA): CP13
(phospho-Ser-202; mouse IgG1); PHF1 (phospho-Ser-396/404; mouse IgG1).54
Immunohistochemistry. Organotypic brain slice cultures were fixed on their
membrane inserts in 4% PFA for 4 h and stained according to Gogolla et al.55 In
brief, slice cultures were cut while still on their membranes and then treated as free-
floating sections. The slice cultures were permeabilised for 18 h in 0.5% Triton
X-100 at 4 °C and then blocked in 20% bovine serum albumin (BSA) for 4 h at RT.
The slice cultures were incubated in total tau and CP13 (as above) primary
antibodies overnight at 4 °C in 5% BSA, washed and then incubated in fluorophore-
coupled secondary antibodies for 4 h at RT. The slice cultures were washed a final
time before mounting on slides with fluorescent mounting medium (Dako Ltd.). The
slice cultures were imaged using an Eclipse Ti-E Inverted (Nikon Instruments,
Kingston Upon Thames, UK) microscope using a CSU-X1 Spinning Disk Confocal
and Andor Ixon3 EM-CCD camera imaging system setup using a 60 Plan Apo VC
N2 objective lens (Nikon Instruments).
Statistics. For slice culture and mouse brain characterisation, data were
analysed by two-way ANOVA followed by Sidak’s post hoc analysis. Tau release
from wild-type and 3xTg-AD slice cultures was analysed by unpaired t-test. Tau
release from these cultures following treatment with KCl and vehicle was assessed
using two-way ANOVA followed by Bonferonni post hoc analysis. Differences were
considered statistically significant when Po0.05. For slice cultures, n refers to each
well which contained three slices.
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